KORU Medical Systems, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $137.8M
- Price
- $2.98
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.50%
- Volume
- 13.7K
About
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
Quick stats
Shares outstanding46.2M
Computed float37.5M
Float / shares81.1%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000704440
Websitehttps://www.korumedical.com
AI Summary
AI-generated1/11
majorbullishearnings
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
KORU Medical Systems reported Q2 2026 revenue of $12.0 million, up 18.2% year-over-year, driven by volume gains in both domestic and international core markets. The company achieved profitability with net income of $0.25 million and positive adjusted EBITDA of $0.9 million, marking a significant operational inflection.
Management executed a strategic pivot by withdrawing its 510(k) application for FreedomEDGE with Phesgo to focus on higher-volume molecules, while simultaneously acquiring a connected monitoring technology asset. A new multi-year supply agreement was also established to support long-term margin expansion.
The company updated full-year 2026 guidance, narrowing revenue expectations to $47.5 million to $48.5 million and raising gross margin targets to 62% to 64%. Cash balance stood at $8.3 million at the end of the quarter.
Red flags
- Pharma services and clinical trials revenue declined 35% year-over-year
- Withdrew 510(k) application for FreedomEDGE with Phesgo in the U.S. to shift strategy